Abstract
This review highlights practical aspects related to aspirin therapy in cardiovascular diseases, specifically, the benefits and hazards in different clinical settings. Aspirin reduces one fourth of all major cardiovascular events but also increases major gastrointestinal bleeds by about half. As with other cardiovascular prevention strategies, the absolute benefit of aspirin is linearly related to the cardiovascular risk of the patient. The risk-benefit of aspirin can vary substantially in different settings: in secondary prevention, the benefits usually outweigh the excess of major bleeding complications. In primary prevention, it is not unusual that the number of vascular events avoided equals the number of major bleeds induced by aspirin. Finally, there is a growing body of evidence suggesting that aspirin may interfere with the early stages of cancer, metastasis and mortality. For all these reasons, in this article new developments in the field directed towards individualized risk assessment strategies are also discussed.
Keywords: Aspirin, prevention cardiovascular diseases, GI damage, proton pump inhibitors.
Current Pharmaceutical Design
Title:A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases
Volume: 21 Issue: 35
Author(s): Rubén Casado-Arroyo, Angel Lanas and Pedro Brugada
Affiliation:
Keywords: Aspirin, prevention cardiovascular diseases, GI damage, proton pump inhibitors.
Abstract: This review highlights practical aspects related to aspirin therapy in cardiovascular diseases, specifically, the benefits and hazards in different clinical settings. Aspirin reduces one fourth of all major cardiovascular events but also increases major gastrointestinal bleeds by about half. As with other cardiovascular prevention strategies, the absolute benefit of aspirin is linearly related to the cardiovascular risk of the patient. The risk-benefit of aspirin can vary substantially in different settings: in secondary prevention, the benefits usually outweigh the excess of major bleeding complications. In primary prevention, it is not unusual that the number of vascular events avoided equals the number of major bleeds induced by aspirin. Finally, there is a growing body of evidence suggesting that aspirin may interfere with the early stages of cancer, metastasis and mortality. For all these reasons, in this article new developments in the field directed towards individualized risk assessment strategies are also discussed.
Export Options
About this article
Cite this article as:
Casado-Arroyo Rubén, Lanas Angel and Brugada Pedro, A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases, Current Pharmaceutical Design 2015; 21 (35) . https://dx.doi.org/10.2174/1381612821666150915110322
DOI https://dx.doi.org/10.2174/1381612821666150915110322 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Stress Modulation Through Habitual Physical Activity
Current Pharmaceutical Design The Role of Omega-3 Polyunsaturated Fatty Acids Supplementation in Childhood: A Review
Recent Patents on Cardiovascular Drug Discovery Editorial (Thematic Issue: Biomarkers of Impaired Innate and Adaptive Immunity in Health and Disease)
Current Immunology Reviews (Discontinued) A Quantitative Structure-Activity Relationship Study on Some Series of Potassium Channel Blockers
Medicinal Chemistry The Economic Costs for the Control of Cardiovascular Risk: An Overview
Current Pharmaceutical Design Association and Causal Relationship of Midlife Obesity and Related Metabolic Disorders with Old Age Cognition
Current Alzheimer Research Pharmacogenetic Modulation of Platelet Inhibition
Current Pharmacogenomics and Personalized Medicine Sleep Apnea and Coronary Heart Disease: From Dusk Till Dawn and Further
Current Respiratory Medicine Reviews Discovery of New Cardiovascular Hormones for the Treatment of Congestive Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Prognostic Value of White Blood Cell Counts and C-reactive Protein in Acute Ischemic Stroke Patients After Intravenous Thrombolysis
Current Neurovascular Research Flavonoid Rich Fraction of Dioscorea bulbifera Linn. (Yam) Enhances Mitochondrial Enzymes and Antioxidant Status, Thereby Protects Heart from Isoproterenol Induced Myocardial Infarction
Current Pharmaceutical Biotechnology [11C]Meta-Hydroxyephedrine PET/CT
Current Radiopharmaceuticals Sleep-Disordered Breathing and Cardiovascular Disease: Exploring Pathophysiology and Existing Data
Current Respiratory Medicine Reviews Treatment of Chronic Peripheral Arterial Disease
Current Vascular Pharmacology Dose Related Patterns of Ventricular Arrhythmia due to Carvedilol Withdrawal in Patients with Systolic Heart Failure
Current Drug Safety Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT): A Prospective-Randomized Study in Middle Aged Men and Women
Current Vascular Pharmacology Gene Therapy to Improve High-Density Lipoprotein Metabolism and Function
Current Pharmaceutical Design Brain Aging in African-Americans: The Atherosclerosis Risk in Communities (ARIC) Experience
Current Alzheimer Research Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences Adjuvant Therapies of COVID-19 - A Literature Review
Coronaviruses